Text Size

Santen CEO Adrienne Graves Joins Board of Glaucoma Research Foundation


San Francisco - November 2, 2009 - The Glaucoma Research Foundation announced today that Adrienne L. Graves, PhD has been appointed to its Board of Directors.

Dr. Graves is President and CEO of Santen Inc., a wholly owned subsidiary of Japan's Santen Pharmaceutical Co., Ltd. (Tokyo Stock Exchange: 4536).

Kuldev Singh, MD, MPH, Board Chair of the Glaucoma Research Foundation and Director of Glaucoma Service and Professor of Ophthalmology at Stanford University, commented, “Having observed the quality of Dr. Graves’ work as a scientist and CEO, I feel she brings tremendous energy, experience and qualifications to the board.”

Thomas M. Brunner, President and CEO of the Glaucoma Research Foundation, added, “The addition of Adrienne Graves will bring a desired and positive skill set and dynamic to our board. We’re proud to have her join what is already a varied and high quality group of medical specialists and professionals.”

Dr. Graves was trained as a visual scientist before beginning her career in the ophthalmic pharmaceutical industry. She studied visual psychophysics and electrophysiology at Brown University, University of Michigan, and University of Paris before joining Alcon Labs. Dr Graves spent 9 years at Alcon before joining Santen in 1995 to help found their U.S. operations.

In addition to her role as President and CEO of Santen Incorporated, she serves as a corporate officer for Santen Pharmaceutical Co., Ltd., and serves on the board of directors for TearLab Corporation. She also serves on the boards of the AAO (American Academy of Ophthalmology) Foundation, the Pan-American Ophthalmological Foundation, and the Corporation Committee for the Brown University Medical School. She co-founded OWL (Ophthalmic Women Leaders) with Dr. Marguerite McDonald.

Last reviewed on October 29, 2017

Was this helpful? Yes No